Polymyxin B-conjugated α2-macroglobulin as an adjunctive therapy to sepsis: Modes of action and impact on lethality

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 762-771

  Birkenmeier, Gerd ^a,g   Nicklisch, Silke ^a   Pockelt, Christiane ^a   Mossie, Andualem ^a   Steger, Volker ^b   Gläser, Christiane ^c   Hauschildt, Sunna ^a   Usbeck, Elke ^a   Huse, Klaus ^d   Sack, Ulli ^e   Bauer, Michael ^f   Schäfer, Angelika ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Emergency and Care Medicine   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d FRITZ LIPMANN INSTITUTE   (Germany)

^e Institute of Clinical Immunology and Transfusion Medicine   (Germany)

^f Clinic for Anesthesiology and Intensive Care   (Germany)

^g Institute of Biochemistry   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; CYTOKINE; FLUORESCEIN ISOTHIOCYANATE; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLACEBO; POLYMYXIN B; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLOOD ANALYSIS; CELL ISOLATION; CELL VIABILITY; CONJUGATE; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPHORESIS; ENDOCYTOSIS; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; LETHALITY; MONOCYTE; MOUSE; NONHUMAN; PHASE PARTITIONING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN TRANSPORT; SEPSIS; SURVIVAL RATE;

ALPHA-MACROGLOBULINS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BLOTTING, WESTERN; CELL SEPARATION; CHRONIC DISEASE; CYTOKINES; DEXTRANS; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIMULUS TEST; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; POLYMYXIN B; RECEPTORS, CYTOKINE; RECEPTORS, DRUG; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745938754     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.104265     Document Type: Article

References (42)

1. Adlakha CL, Hart JP, and Pizzo SV (2001) Kinetics of nonproteolytic incorporation of a protein ligand into thermally activated α2- macroglobulin: evidence for a novel nascent state. J Biol Chem 276:41547-41552.
2. Berger M and Pinciaro PJ; Flebogamma 5% Investigators (2004) Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24:389-396.
3. Bernhagen J, Calandra T, and Bucala R (1994) The emerging role of MIF in septic shock and infection. Biotherapy 8:123-127.
4. Birkenmeier G (2001) Targetting the protease inhibitor and immune modulatory function of human α2 macroglobulin. Mod Aspects Immunobiol 2:32-36.
5. Birkenmeier G, Carlsson-Bostedt L, Shanbhag V, Kriegel T, Kopperschlager G, Sottrup-Jensen L, and Stigbrand T (1989a) Differences in hydrophobic properties for human alpha 2-macroglobulin and pregnancy zone protein as studied by affinity phase partitioning. Eur J Biochem 183:239-243.
6. Birkenmeier G, Heidrich K, Glaser C, Handschug K, Fabricius EM, Frank R, and Reissig D (1989b) Different expression of the alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein in human keratinocytes and fibroblasts. Arch Dermatol Res 290:561-568.
7. Birkenmeier G, Muller R, Huse K, Forberg J, Glaser C, Hedrich H, Nicklisch S, and Reichenbach A (2003) Human alpha2-macroglobulin: genotype-phenotype relation. Exp Neurol 184:153-161.
8. Bocher M, Boldicke T, Kiess M, and Bilitewski U (1997) Synthesis of mono- and bifunctional peptide-dextran conjugates for the immobilization of peptide antigens on ELISA plates: properties and application. J Immunol Methods 208:191-202.
9. Bucklin S, Lake P, Lögdberg L, and Morrison DC (1995) Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob Agents Chemother 39:1462-1466.
10. Burgess JW and Stanley KK (1997) Estrogen-stimulated transcytosis of desialylated ligands and alpha2-macroglobulin in rat liver. Biochim Biophys Acta 1359:48-58.
11. Danai P and Martin GS (2005) Epidemiology of sepsis: recent advances. Curr Infect Dis Rep 7:329-334.
12. Danner RL, Joiner KA, Rubin M, Patterson WH, Johnson N, Ayers KM, and Parrillo JE (1989) Purification, toxicity and antiendotoxin activity of polymyxin B non-apeptide. Antimicrob Agents Chemother 33:1428-1434.
13. Deans KJ, Haley M, Natanson C, Eichacker PQ, and Minneci PC (2005) Novel therapies for sepsis: a review. J Trauma 58:867-874.
14. De Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F, Pirenne J, Gathy R, Lopez M, and Dehart I (1992) Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine 4:239-248.
15. Drabick J Bhattacharjee AK, Hoover DL, Siber GE, Morales VE, Young LD, Brown SL, and Cross AS (1998) Covalent polymyxin-B conjugate with human immunoglobulin-G as an antiendotoxin reagent. Antimicrob Agents Chemother 42:583-588.
16. Esmon CT (2004) Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 32:219-222.
17. Gerth A, Grosche J, Nieber K, and Hauschildt S (2005) Intracellular LPS inhibits the activity of potassium channels and fails to activate NFkappaB in human macrophages. J Cell Physiol 202:442-452.
18. Gonias SL, LaMarre J, Crookston KP, Webb DJ, Wolf BB, Lopes MB, Moses HL, and Hayes MA (1994) alpha 2-Macroglobulin and the alpha 2-macroglobulin receptor/LRP. A growth regulatory axis. Ann NY Acad Sci 737:273-290.
19. Gourine AV, Tesfaigzi Y, Caluwaerts N, Leuven FN, and Kluger MJ (2002) The role of α2 macroglobulin on fever and cytokine response induced by LPS in mice. Am J Physiol 283:218-226.
20. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, and Stanley KK (1988) Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to LDL receptor suggest a physiological role as a lipoprotein receptor. EMBO (Eur Mol Biol Organ) J 7:4119-4127.
21. Laemmli UK (1970) Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature (Lond) 227:680.
22. Lake P, DeLeo J, Cerasoli F, Logdberg L, Weetall M, and Handley D (2004) Pharmacodynamic evaluation of the neutralization of endotoxin by PMX622 in mice. Antimicrob Agents Chemother 48:2987-2992.
23. LaMarre J, Wollenberg GK, Gonias SL, and Hayes MA (1991) Cytokine binding and clearance properties of protease activated α2 macroglobulin. Lab Investig 65:3-14.
24. Lauer D, Reichenbach A, and Birkenmeier G (2001) alpha 2-Macroglobulin-mediated degradation of amyloid beta 1-42: a mechanism to enhance amyloid beta catabolism. Exp Neurol 167:385-392.
25. Llewelyn M and Cohon J (1999) Anti-endotoxin antibodies in sepsis: a critical evaluation. Sepsis 3:39-45.
26. Lukyanov AN, Sawant RM, Hartner WC, and Torchilin VP (2004) PEGylated dextran as long-circulating pharmaceutical carrier. J Biomater Sci Polym Ed 15:621-630.
27. McNamara MJ, Norton JA, Nauta RJ, and Alexander HR (1993) Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice. J Surg Res 54:316-321.
28. Neter E (1956) Bacterial hemagglutination and hemolysis. Bacteriol Rev 20:166-188.
29. Nooteboom A, Van der Linden CJ, and Hendriks T (2002) Tumor necrosis factor-alpha and interleukin-1beta mediate endothelial permeability induced by lipopolysaccharide-stimulated whole blood. Crit Care Med 30:2063-2068.
30. Reinhart K and Karzai W (2001) Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 29:121-125.
31. Riedemann NC, Guo RF, and Ward PA (2003) Novel strategies for the treatment of sepsis. Nat Med 9:517-524.
32. Singleton KD and Wischmeyer PE (2003) Distance of cecum ligated influences mortality, tumor necrosis factor-alpha and interleukin-6 expression following cecal ligation and puncture in the rat. Eur Surg Res 35:486-491.
33. Sottrup-Jensen L (1989) α-Macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 264:11539-11542.
34. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, and Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (Lond) 330:662-664.
35. Warren HS, Amato SF, Fitting C, Black KM, Loiselle PM, Pasternack MS, and Cavaillon JM (1993) Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 177:89-97.
36. Webb DJ and Gonias SL (1998) A modified human alpha 2-macroglobulin derivative that binds tumor necrosis factor-alpha and interleukin-1 beta with high affinity in vitro and reverses lipopolysaccharide toxicity in vivo in mice. Lab Investig 78:939-948.
37. Williams SE, Ashcom JD, Argraves WS, and Strickland DK (1992) A novel mechanism for controlling the activity of α2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptorassociated protein. J Biol Chem 267:9035-9040.
38. Wilson BM, Severn A, Rapson NT, Chana J, and Hopkins P (1991) A convenient human whole blood culture system for studying the regulation of tumour necrosis factor release by bacterial lipopolysaccharide. J Immunol Methods 139:233-240.
39. Wollenberg GK, LaMarre J, Rosendal S, Gonias SL, and Hayes MA (1991) Binding of tumor necrosis factor alpha to activated forms of human plasma alpha 2-macroglobulin. Am J Pathol 138:265-272.
40. Wu SM, Patel DD, and Pizzo SV (1998) Oxidized alpha2-macroglobulin (alpha2M) differentially regulates receptor binding by cytokines/growth factors: implications for tissue injury and repair mechanisms in inflammation. J Immunol 161:4356-4365.
41. Yang H, Wang H, Czura CJ, and Tracey KJ (2005) The cytokine activity of HMGB1. J Leukoc Biol 78:1-8.
42. Yethon JA and Whitfield C (2001) Lipopolysaccharide as a target for the development of novel therapies in Gram-negative bacteria. Curr Drug Targets Infect Disord 1:91-106.